ArticleJournal of cosmetic dermatology2025
A Rare Case of Delayed-Onset Hypersensitivity Reaction and Complete Secondary Treatment Failure Following Repeated Cosmetic Botulinum Toxin Type A Injections.
Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dexamethasone Admixture for Hypersensitivity Prevention in Botulinum Toxin Type A Treatment: A Case Report.Journal of cosmetic dermatology · 2026Article
- Serum Sickness After Cosmetic Botulinum Toxin Type A Injections.Aesthetic surgery journal. Open forum · 2026Article
- Hypersensitivity Reactions Associated With Aesthetic Botulinum Toxin A Injections: A Case Series.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCosmetic botulinum toxin type A (BTX-A) injections have been widely used for improving facial aesthetics. Although the procedure is generally safe, immune-mediated adverse events, such as hypersensitivity reactions and secondary treatment failures, may rarely occur. We report the first case in which repeated BTX-A injections resulted in both a delayed-onset cutaneous hypersensitivity reaction and complete secondary treatment failure. CASE REPORT/
methodsA 42-year-old female, with a history of successful BTX-A treatments for glabellar lines and masseter hypertrophy, experienced diminished efficacy following a treatment session. Ten hours after a touch-up injection, she developed facial swelling and edematous erythema localized to the injection sites. These manifestations persisted for over one month without any observable aesthetic improvement, indicating complete secondary treatment failure. The therapeutic effect was not restored even after switching to an alternative BTX-A formulation. We hypothesize that the patient's local hypersensitivity reaction represents a type III immune complex-mediated response (Arthus reaction) driven by IgG antibodies. The repeated BTX-A injections may have induced neutralizing IgG antibodies that, in concert with the cutaneous hypersensitivity reaction, contributed synergistically to both the cutaneous reaction and the complete treatment failure. The short interval between the injections may have facilitated these immunologic events.
conclusionThis case underscores the importance for clinicians to remain vigilant regarding the potential for delayed-onset cutaneous allergic reactions and complete secondary treatment failure following repeated BTX-A injections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.